Day One Biopharmaceuticals, Inc. (DAWN)
Day One Biopharmaceuticals, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Brisbane, CA, US. The stock last traded at $21.53, up 0.00% on the session, giving a market capitalisation of $2.22B. On trailing twelve-month figures it carries a trailing P/E of -20.70, a net margin of -67.8%. Its beta of -1.75 implies it has historically moved less than the broad market.
Operating as a clinical-stage biopharmaceutical entity, Day One Biopharmaceuticals, Inc. is dedicated to discovering and commercializing precise therapeutic options for individuals battling genetically defined cancers. A key asset is DAY101, an orally administered, brain-permeable type II pan-rapidly accelerated fibrosarcoma kinase inhibitor, currently undergoing Phase II clinical trials for young patients experiencing recurrent or worsening low-grade glioma. Additionally, the company is advancing Pimasertib, an oral small molecule designed to inhibit mitogen-activated protein kinase kinases 1 and 2. Established in 2018, Day One Biopharmaceuticals, Inc. maintains its primary operations in South San Francisco, California.
Day One Biopharmaceuticals, Inc. is most often compared with the following Healthcare names: